Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-AD: 3TC for Early Alzheimer's Disease
NCT04552795Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lamivudine in Alzheimer's disease (AD), sponsored by UT Health San Antonio. Primary endpoints: Change in Reverse Transcriptase Activity From Baseline to 24 Weeks in Plasma and 3TC CNS Penetration at 24 weeks. Started Feb 2021; status: completed.
02
Drugs
lamivudine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04552795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552795.